Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.

Pratley RE, Tuttle KR, Rossing P, Rasmussen S, Perkovic V, Nielsen OW, Mann JFE, MacIsaac RJ, Kosiborod MN, Kamenov Z, Idorn T, Hansen MB and 4 more

Show all authors

Hadjadj S, Bakris G, Baeres FMM, Mahaffey KW

Journal of the American College of Cardiology30 Aug 2024Cited by 90 (Europe PMC)

PMID39217553DOI10.1016/j.jacc.2024.08.004PepBankPUB-39217553

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and chronic kidney disease, semaglutide lowered the risk of the composite of heart failure events or cardiovascular death versus placebo.
In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide lowered the risk of heart failure events or heart death more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHeart failure events or cardiovascular death, overall population
Study
n = 3,533
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1 mg once weekly · subcutaneous · median follow-up 3.4 yearsAs given in this study (human).
Measurements
hazard ratio
0.73 ratio
overall population
Source sentences
Summary
semaglutide increased time to first HF events or CV death (HR: 0.73; 95% CI: 0.62-0.87; P = 0.0005)
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized (1:1) to once-weekly subcutaneous semaglutide 1 mg or placebo.
Report a problemFND-3921755301
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and chronic kidney disease, semaglutide lowered the risk of heart failure events alone versus placebo.
In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide lowered the risk of heart failure events more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHeart failure events alone, overall population
Study
n = 3,533
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1 mg once weekly · subcutaneous · median follow-up 3.4 yearsAs given in this study (human).
Measurements
hazard ratio
0.73 ratio
overall population
Source sentences
Summary
HF events alone (HR: 0.73; 95% CI: 0.58-0.92; P = 0.0068)
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized (1:1) to once-weekly subcutaneous semaglutide 1 mg or placebo.
Report a problemFND-3921755302
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and chronic kidney disease, semaglutide lowered the risk of cardiovascular death alone versus placebo.
In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide lowered the risk of death from heart causes more than placebo.
Peptide
Semaglutide
Outcome
DecreaseCardiovascular death alone, overall population
Study
n = 3,533
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1 mg once weekly · subcutaneous · median follow-up 3.4 yearsAs given in this study (human).
Measurements
hazard ratio
0.71 ratio
overall population
Source sentences
Summary
CV death alone (HR: 0.71; 95% CI: 0.56-0.89; P = 0.0036)
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized (1:1) to once-weekly subcutaneous semaglutide 1 mg or placebo.
Report a problemFND-3921755303
04HumanRandomized controlled trialEfficacy outcome
In participants with heart failure at baseline, semaglutide lowered the risk of the composite heart failure outcome versus placebo.
In plain wordsIn people who already had heart failure, semaglutide lowered the risk of heart failure events or heart death more than placebo.
Peptide
Semaglutide
Outcome
DecreaseComposite heart failure outcome in participants with heart failure at baseline
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1 mg once weekly · subcutaneous · median follow-up 3.4 yearsAs given in this study (human).
Measurements
hazard ratio
0.73 ratio
with heart failure at baseline
Source sentences
Summary
The risk reduction for the composite HF outcome was similar in those with (HR: 0.73; 95% CI: 0.54-0.98; P = 0.0338) and without (HR: 0.72; 95% CI: 0.58-0.89; P = 0.0028) HF at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized (1:1) to once-weekly subcutaneous semaglutide 1 mg or placebo.
Report a problemFND-3921755304
05HumanRandomized controlled trialEfficacy outcome
In participants without heart failure at baseline, semaglutide lowered the risk of the composite heart failure outcome versus placebo, similar to those with heart failure.
In plain wordsIn people without heart failure at the start, semaglutide also lowered the risk of heart failure events or heart death more than placebo.
Peptide
Semaglutide
Outcome
DecreaseComposite heart failure outcome in participants without heart failure at baseline
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1 mg once weekly · subcutaneous · median follow-up 3.4 yearsAs given in this study (human).
Measurements
hazard ratio
0.72 ratio
without heart failure at baseline
Source sentences
Summary
The risk reduction for the composite HF outcome was similar in those with (HR: 0.73; 95% CI: 0.54-0.98; P = 0.0338) and without (HR: 0.72; 95% CI: 0.58-0.89; P = 0.0028) HF at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants were randomized (1:1) to once-weekly subcutaneous semaglutide 1 mg or placebo.
Report a problemFND-3921755305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Novo Nordisk A/Sn = 3,53317 Jun 2019 to 9 Jan 2024

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 20 Mar 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.